GR antagonists, such as mifepristone or relacorilant could reverse chemotherapy resistance and potentiate chemotherapy-induced apoptosis in triple-negative breast cancer, pancreatic cancer, and ovarian cancer cell lines [12,82]. This evidence concerns the gene NR3C1 and triple-negative breast carcinoma.